Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GRM8 | O00222 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892280 | 1.00 | FFAR3 (0.56) | FFAR3GRM2GRM3GRM4CYP2C19 | |
| SCHEMBL15733215 | 0.87 | FFAR3 (0.46) | FFAR3GRM2GRM3GRM4CYP2C19 | |
| SCHEMBL13740389 | 0.87 | FFAR3 (0.46) | FFAR3GRM2GRM3GRM4CYP2C19 | |
| SCHEMBL431288 | 0.84 | FFAR3 (0.59) | FFAR3GRM2GRM3GRM4CYP2C19 | |
| SCHEMBL11799188 | 0.84 | FFAR3 (0.59) | FFAR3GRM2GRM3GRM4CYP2C19 | |
| SCHEMBL16094029 | 0.83 | FFAR3 (0.52) | FFAR3GRM2GRM3GRM4CYP2C19 | |
| SCHEMBL23458958 | 0.81 | FFAR3 (0.62) | FFAR3GRM2GRM3GRM4CYP2C19 | |
| SCHEMBL21834034 | 0.80 | FFAR3 (0.54) | FFAR3GRM2GRM3GRM4CYP2C19 | |
| SCHEMBL21834030 | 0.80 | FFAR3 (0.54) | FFAR3GRM2GRM3GRM4CYP2C19 | |
| SCHEMBL19919700 | 0.80 | FFAR3 (0.54) | FFAR3GRM2GRM3GRM4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | LIPOCALYX GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-20100022621-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | MDRNA RESEARCH, INC. | 2010-01-28 | — | — | US | disclosed |
| EP-2125029-A2 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | Novosom AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008074488-A2 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | NOVOSOM AG (DE) | 2008-06-26 | — | — | WO | disclosed |
| EP-0705817-A1 | New cannamide derivatives and their use as allergy inhibitors | TSUMURA & CO. (JP) | 1996-04-10 | — | — | EP | disclosed |
| US-5344845-A | Methyl 4(4-acetoxy-3-methoxycinnamanide and salts as an immunosuppressive drug for allergic reactions | TSUMURA & CO. (JP) | 1994-09-06 | — | — | US | disclosed |
| EP-0535250-A1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO. (JP) | 1993-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022621-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | TEAD4, CREB1, ELF3 | FFAR3 3779/4885GRM2 3965/4885GRM3 3988/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | FFAR3 1249/4885GRM2 2381/4885GRM3 3286/4885 |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | TEAD4, CREB1, ELF3 | FFAR3 3779/4885GRM2 3965/4885GRM3 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.